Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Healthcare diagnostics catalyst with improving fundamentals: on 2026-08-05 Q2 revenue rose 45% YoY to $263.7M, full-year 2026 guidance was raised to $1.03B-$1.04B, and Caris Detect plus PTEN IHC testing expansion add product momentum.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin Expansion ⢠Liquidity Strength ⢠Rising Leverage CAI shows improving operations and strong liquidity, but fragile profitability, rising leverage, declining cash, and expensive valuation warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Key support ⢠Weak momentum Support Level: $24.00â$24.30 Resistance Level: $25.30â$25.65 CAI remains constructive over the last month but near-term bearish unless it holds $24.00â$24.30 and reclaims $25.30â$25.65.
Sentiment & News
Key News Insights: ⢠AI Treatment Selection ⢠Lung Cancer Research ⢠National Test Campaign Caris advanced AI-guided oncology treatment research, expanded lung-cancer studies, and boosted nationwide awareness of its early-detection blood test.
AI Summary
CAI is transitioning into a scalable diagnostics business, but its premium valuation now requires proof that 45% revenue growth, expanding margins, and positive EBITDA can translate into sustained net income and free cash flow; investors should prioritize evidence of reimbursed Caris Detect adoption and durable cash generation before adding exposure.
Description
Caris Life Sciences is a US-based provider of molecular profiling services and related laboratory and data offerings to clinical and biopharmaceutical customers worldwide. The company supplies tissue- and blood-based tests for cancer treatment selection and supports drug development through laboratory execution, data products, and research services. Founded in 2008, Caris is headquartered in Irving, Texas.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 6 | Aug 13 | CAI | Caris Life Sciences, Inc. | Healthcare diagnostics catalyst with improving fundamentals: on 2026-08-05 Q2 revenue rose 45% YoY to $263.7M, full-year 2026 guidance was raised to $1.03B-$1.04B, and Caris Detect plus PTEN IHC testing expansion add product momentum. | Closed | +10.9% |
| Jun 26 | Jul 3 | CAI | Caris Life Sciences, Inc. | CAI has favorable near-term momentum and business catalysts: Q1 revenue rose 79% YoY to $216.2M, recent updates include product launch activity, MolDX approval, New York authorization filing, clinical validation progress, expanded oncology network, a $100M buyback authorization, and about 17.8% stock gain over 21 trading days. | Closed | -1.1% |
| Jun 18 | Jun 25 | CAI | Caris Life Sciences, Inc. | Constructive momentum plus catalysts: Q1 2026 revenue grew 79% YoY to $216.2M with positive free cash flow, liquidity is strong, and recent supports include a $100M buyback authorization and MolDX approval for Caris ChromoSeq. | Closed | +1.3% |
| Jun 9 | Jun 16 | CAI | Caris Life Sciences, Inc. | Positive catalyst stack with Q1 2026 revenue of $216.2M, up 79% YoY, plus Caris MI Clarity launch, Caris ChromoSeq launch and MolDX approval, NY State authorization filing for Caris Assure, and a $100M share repurchase program announced on 2026-06-08. | Closed | +6.0% |